Iradimed (IRMD) Liabilities and Shareholders Equity (2013 - 2026)

Iradimed has reported Liabilities and Shareholders Equity for 14 years, with the latest figure at $115.0 million in Q2 2026.

• Liabilities and Shareholders Equity for Q2 2026 came in at $115.0 million, up 8.01% year-over-year; the trailing twelve-month figure through Jun 2026 was $452.9 million (up 13.0% YoY), and the FY2025 annual result was $108.8 million, up 10.63% from the prior year.
• Liabilities and Shareholders Equity improved to $115.0 million in Q2 2026, from $114.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $115.0 million in Q2 2026 and troughed at $72.4 million in Q1 2022.
• A 5-year average of $93.4 million and a median of $91.1 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity climbed 0.19%; it then increased 21.72% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $85.5 million in 2022, then rose by 7.77% to $92.2 million in 2023, then gained by 6.7% to $98.3 million in 2024, then advanced by 10.63% to $108.8 million in 2025, then climbed by 5.7% to $115.0 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $115.0 million in Q2 2026, $114.4 million in Q1 2026, and $108.8 million in Q4 2025.